Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

With patents locked up into the 2030s and rivals nowhere in sight, Vertex's CF fortress looks impregnable. The company has methodically built this position through years of innovation, leaving ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

"FDA approves Vertex’s acute pain treatment Journavx" was originally created and published by Pharmaceutical Technology, a ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3% ...

The past week has proven to be lucrative for Vertex Pharmaceuticals investors, so let's see if fundamentals drove the company's five-year performance. There is no denying that markets are ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...